Sequenta

The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.

Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.

Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.

Researchers are demonstrating that sequencing the immune repertoire can offer valuable insight into blood cancers, treatment response, and the likelihood of relapse.

NEW YORK (GenomeWeb) – Sequenta said this week that biopharmaceutical firm Celgene and others have made an equity investment into the company.

The University of Massachusetts has been awarded

Korea Institute of Science and Technology has been awarded

This article has been updated with additional details about the ClonoSIGHT test and to clarify that Sequenta is in discussions with the FDA to transition the diagnostic from a lab test to a kit.

Foundation Medicine has launched FoundationOne Heme, a next-generation sequencing-based test that looks for genomic alterations in 405 genes related to hematological cancers. The test also incorporates RNA sequencing of 265 genes to look for gene fusions.

Pages

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.